logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5471.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5471.produseast1
Homepage featured | Collections | MSF Science Portal
Homepage featured

Homepage featured

Collection Content

Journal Article
|
Research

Risk stratification of childhood infection using host markers of immune and endothelial activation in Asia (Spot Sepsis): a multi-country, prospective, cohort study

Chandna A, Koshiaris C, Mahajan R, Ahmad RA, Van Anh DT,  et al.
2025-09-01 • Lancet Child and Adolescent Health
2025-09-01 • Lancet Child and Adolescent Health

BACKGROUND

Prognostic tools for febrile illnesses are urgently required in resource-constrained community contexts. Circulating immune and endothelial activatio...

Journal Article
|
Letter

War wounds caused by explosive weapons in Gaza: data from a 2024 study by Médecins Sans Frontières

Nicolai M, Safi SSS, Casera M, Dekhili D, Hook C,  et al.
2025-07-01 • Lancet
2025-07-01 • Lancet
Journal Article
|
Pre-Print

Feasibility and acceptability of menstrual underwear in a conflict and population displacement prone setting of Kalehe, Democratic Republic of the Congo

Bisimirwe C, Maombi S, Nabuki S, Mubelelwa L, Llosa AE,  et al.
2025-06-29 • Research Square
2025-06-29 • Research Square

Menstrual hygiene management remains a critical yet often neglected issue in humanitarian setting. Reusable menstrual underwear (MU) offers a potentially sustainable and discrete solu...

Conference Material
|
Abstract

Newly discovered paediatric melioidosis in Mali: the tip of an African iceberg?

Lichtenegger S, Michel J, Mollo B, Sanogo A, Diawara H,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Journal Article
|
Short Report

Providing emergency medical care at the Belarus-Poland border

Zadykowicz R, Kuc J, Ladomirska J, Zamatto F, Lim SY
2025-05-01 • Forced Migration Review
2025-05-01 • Forced Migration Review
Journal Article
|
Research

High caseload of Scabies amongst Rohingya refugees in Cox’s Bazar, Bangladesh: a retrospective analysis of the epidemiological and clinical characteristics of cases, July 2022 to November 2023

Alhaffar BA, Islam S, Hoq MI, Das A, Shibloo SM,  et al.
2025-04-09 • PLOS Global Public Health
2025-04-09 • PLOS Global Public Health

Scabies is a dermatological parasitic infestation prevalent in many regions worldwide. Classified as a neglected disease by World Health Organization (WHO) since 2017, it is often ass...

See more collections

Combatting antibiotic resistance 2022
Combatting antibiotic resistance 2022
Resistance to antibiotics is a growing public health crisis, especially in countries with fragile health systems and in regions at war. The World Health Organization has estimated that antibiotic-resistant bacteria caused nearly 1.3 million deaths in 2019, a toll that will increase significantly in the coming years if effective action is not taken. To mark World Antimicrobial Awareness Week 2022 (18-24 November) we present a snapshot of MSF’s recent work on responding to this growing threat. Since many humanitarian settings lack laboratory capacity to diagnose these infections, MSF and partners have developed two new technologies with the potential to dramatically expand the availability of accurate diagnosis—allowing clinicians to then tailor antibiotic treatment accordingly. Other work from diverse contexts describes practices and challenges related to optimizing rational antibiotic use within health facilities and communities. Lastly, several studies characterize the patterns and prevalence of antibiotic resistance among MSF patients, from hospitalized neonates in Central African Republic to acute trauma patients in Haiti and Yemen.
MSF logo
Costs, cost-effectiveness, and financing of tuberculosis trea...

Tuberculosis (TB) is the world's deadliest infectious disease, and the leading killer of people with HIV. TB is curable, but it can be difficult to diagnose and tough to treat, especially for increasingly prevalent drug-resistant TB. In 2023, 22,700 people started TB treatment in MSF programs. Understanding the costs and cost-effectiveness associated with TB treatment and innovations, ranging from TB diagnostics and medications to TB care models, can help to plan resource needs and allocate resources effectively. Analyzing financing mechanisms can support developing sustainable funding models for TB control.

This collection spotlights articles by MSF and collaborators to analyze and document the costs of care, particularly diagnostics and medications.

MSF logo
Epicentre Scientific Day Paris 2023
No description available
View All Collections